AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AstraZeneca Pharma to launch eculizumab in India in August
ByAinvest
Wednesday, Aug 6, 2025 5:33 am ET1min read
AstraZeneca Pharma to launch eculizumab in India in August
AstraZeneca Pharma has announced plans to launch its biosimilar eculizumab in the Indian market in August 2025. Eculizumab, marketed under the brand name Soliris, is a monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).The launch of eculizumab in India marks a significant step for AstraZeneca, which has been expanding its biosimilar portfolio globally. The company has been focusing on biosimilars to enhance patient access to high-quality, affordable biologic medicines. This move aligns with AstraZeneca's strategic goal to bring innovative and effective treatments to patients in emerging markets.
The Indian market presents a large opportunity for biosimilar growth due to its high prevalence of chronic diseases and an increasing demand for affordable healthcare solutions. According to a report by SkyQuest Technology Consulting, the global biopharmaceutical market is projected to reach USD 948.6 billion by 2032, driven by advancements in biotechnology and the rising need for targeted treatments [2].
Samsung Bioepis, a leading biosimilar developer, recently presented long-term safety data for its biosimilar eculizumab, Epysqli, at the European Hematology Association Congress 2025. This underscores the potential for biosimilars to provide comparable efficacy and safety to their reference products [1].
AstraZeneca's launch of eculizumab in India is expected to strengthen its position in the competitive biosimilar landscape. The company's strategic focus on biosimilars is part of a broader effort to enhance patient access and improve healthcare outcomes globally.
References:
[1] https://www.thepharmaletter.com/biosimilars
[2] https://menafn.com/1109868791/Biopharmaceuticals-Market-Is-Estimated-To-Reach-USD-9486-Bilion-By-2032-Skyquest-Technology-Consulting
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet